Scientific Presentations & Publications

Title Published Date
Scientific Presentations and Publications Referenced in Current Corporate Presentation Jul 01 2024
Notable Labs Reports 2023 Financial Results and Provides a Business Update Apr 12 2024
AACR 2024 VOLA Poster Apr 09 2024
AACR 2024 Poster Apr 08 2024
Notable Labs - Translating AI to real-world outcomes: Unlocking the future of drug development at Notable Labs Mar 06 2024
Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform Mar 05 2024
Notable Labs Presents Data Demonstrating PPMP’s Potential to Identify Novel Drug Combinations in JMML at the 2023 EHA Hybrid Congress Jun 09 2023
Predictive precision medicine platform accurately predicts individual patient response to AML treatments to maximize outcomes Apr 18 2023
Notable Labs Presents Clinical Platform Validation Data at the 2023 AACR Conference Apr 18 2023
Ex Vivo Drug Sensitivity Correlates with Clinical Response and Supports Personalized Therapy in Pediatric AML- Advances in Pediatric Acute Myeloid Leukemia Jan 18 2023
Successful Treatment with Bortezomib, Panobinostat, and Dexamethasone of Acute Myeloid Leukemia (AML) in 2nd Relapse After Allogeneic Stem Cell Transplantation (SCT): Therapy Selected Based Upon Results of a Personalized Flow Cytometric Screen for Drug Aug 11 2022
Ex Vivo Drug Sensitivity Assay Correlates with Clinical Response and Identifies Panobinostat and Bortezomib as a Potential Novel Drug Combination for Pediatric AML Dec 16 2021
Prediction of clinical response to venetoclax plus decitabine in AML using a 7-day ex vivo assay Dec 16 2021
Ex vivo drug sensitivity assay correlates with clinical response in pediatric AML Jul 21 2021
Correlation of ex vivo drug sensitivity with clinical response in pediatric AML Jul 21 2021
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia Mar 12 2021
Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms Oct 09 2020
Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion- positive AML Defines Novel Therapeutic Options – A COG and TARGET Pediatric AML Study Oct 08 2020
PTC299 Is a Novel DHODH Inhibitor That Modulates VEGFA mRNA Translation and Inhibits Proliferation of a Broad Range of Leukemia Cells Jul 11 2020
Ex Vivo High-Throughput Flow Cytometry Screening Identifies Subsets of Responders to Differentiation Agents in Individual AML Patient Samples Jul 02 2020

Page 1 of 2

To learn more, share ideas, or join our mission.
Contact us today!


We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.